Novavax (XSWX:NVAX) FFO


XSWX:NVAX Novavax Inc XSWX:NVAX
50 GF Score
Price CHF7.61
GF Value CHF3.14
! 7 Warning Signs
View Full Analysis

What is Novavax FFO?

FFO (Funds from operations) only applies to REITs.

XSWX:NVAX
50GF Score
Novavax Inc XSWX:NVAX
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Novavax (XSWX:NVAX) Overvalued in 2026?

Based on GuruFocus' analysis, Novavax stock appears to be overvalued. The current stock price of CHF7.61 is trading 142.4% above its estimated GF Value™ of CHF3.14.

Key valuation signals for XSWX:NVAX:

  • FFO:
  • GF Value™: CHF3.14 vs. price of CHF7.61 (142.4% above fair value)
  • GF Score™: 50/100 with 7 warning signs

No single metric tells the full story. See the XSWX:NVAX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Novavax Business Description

Address 21 Firstfield Road, Gaithersburg, MD, USA, 20878
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.
50GF Score

Get the complete analysis for XSWX:NVAX

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF7.61
Price
CHF3.14
GF Value